Plain-English translation of NCT06266832 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of three treatments—short-course radiation therapy, a new immunotherapy drug called , and chemotherapy—can shrink rectal cancer tumors so effectively that surgery to remove the rectum may not be needed. The study focuses on people with a specific type of early rectal cancer that starts very close to the anus. The goal is to help patients keep their rectum and avoid permanent colostomy if possible.
Currently, most people with rectal cancer need surgery to remove the entire rectum, which permanently changes how the body works. This trial explores whether adding immunotherapy to radiation and chemotherapy might work well enough to let some patients keep their rectum, which would greatly improve their quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy (a short 5-day course delivering 25 Gy), followed by two rounds of intravenous infusions of combined with chemotherapy (CAPEOX). After finishing the medication treatment, you would have a biopsy or small tissue sampling procedure 1–4 weeks later to see how well the treatment worked. Throughout this process, you'll have regular hospital visits for imaging, blood tests, and follow-up examinations to monitor your response and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China